Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKarakuyu, N. F.
dc.contributor.authorKaya, M. N.
dc.contributor.authorSofu, G. Usta
dc.contributor.authorSarman, E.
dc.date.accessioned2025-12-28T16:40:00Z
dc.date.available2025-12-28T16:40:00Z
dc.date.issued2025
dc.identifier.issn0014-4835
dc.identifier.issn1096-0007
dc.identifier.urihttps://doi.org/10.1016/j.exer.2025.110464
dc.identifier.urihttps://hdl.handle.net/20.500.12933/2312
dc.description.abstractCorneal injuries, particularly those caused by alkaline substances, are challenging to treat and can lead to severe complications such as inflammation, ulceration, and blindness. Current treatments, including lavage, antibiotics, and steroids, often fail to provide rapid or complete recovery. Theranekron, a homeopathic preparation derived from the venom of the Tarantula cubensis spider, has shown anti-inflammatory and wound-healing properties in veterinary medicine. This study aimed to investigate Theranekron's potential in treating corneal damage in a rat model. Thirty-two rats were divided into four groups: damage, damage + dexamethasone, damage + ocular Theranekron, and damage + subcutaneous Theranekron. Corneal damage was induced using silver/potassium nitrate sticks, and treatments were administered for seven days. Clinical, histopathological, and immunohistochemical evaluations were conducted to assess inflammation, neovascularization, and tissue repair. Rats treated with Theranekron (both ocular and subcutaneous) showed significant reductions in inflammation, edema, and neovascularization compared to the untreated and dexamethasone groups. Immunohistochemical analysis revealed lower expression of inflammatory markers (TNF-alpha, NF-kappa B-p65) and VEGF in Theranekron-treated groups. Theranekron exhibited significant potential in promoting corneal healing by reducing inflammation and inhibiting neovascularization. Its effectiveness exceeds dexamethasone's, making it a promising alternative for treating corneal injuries. Further research is needed to explore its application in human ocular medicine and to optimize dosing and administration methods.
dc.description.sponsorshipScientific and Technological Research Council of Turkiye [2209-A]
dc.description.sponsorshipThis study was supported by the Scientific and Technological Research Council of Turkiye (2209-A support program) , with application number 1919B012322253.
dc.language.isoen
dc.publisherAcademic Press Ltd- Elsevier Science Ltd
dc.relation.ispartofExperimental Eye Research
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCornea
dc.subjectRat
dc.subjectTheranekron
dc.titleHealing effect of homeopathic drug Theranekron in an alkaline-induced corneal injury model in rats
dc.typeArticle
dc.identifier.orcid0000-0002-0065-4384
dc.identifier.orcid0009-0005-6978-2914
dc.identifier.orcid0000-0002-2249-4668
dc.departmentAfyonkarahisar Sağlık Bilimleri Üniversitesi
dc.identifier.doi10.1016/j.exer.2025.110464
dc.identifier.volume258
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.department-temp[Karakuyu, N. F.] Suleyman Demirel Univ, Fac Pharm, Dept Pharmacol, Isparta, Turkiye; [Kaya, M. N.] Suleyman Demirel Univ, Fac Pharm, Isparta, Turkiye; [Sofu, G. Usta] Suleyman Demirel Univ, Fac Med, Dept Ophthalmol, Isparta, Turkiye; [Sarman, E.] Afyonkarahisar Hlth Sci Univ, Fac Med, Dept Histol & Embryol, Afyonkarahisar, Turkiye
dc.identifier.pmid40480597
dc.identifier.scopus2-s2.0-105007321518
dc.identifier.scopusqualityQ1
dc.identifier.wosWOS:001508243000001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.snmzKA_WoS_20251227


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster